| Popis: |
Background: Prophylactic human papilloma virus (HPV) vaccines represent a promising option for cervical cancer (CC) prevention in countries where screening, diagnostics and treatment have difficulties in producing significant reductions in CC incidence/mortality. Numerous studies have evaluated the cost-effectiveness of HPV vaccination strategies including female vaccination alone, female vaccination combined with different screening strategies, or female and male vaccination. Countries with the highest CC incidences, however, have the least resources to implement any CC prevention programs. To understand priorities in low vs. middle income countries with high CC incidence pertinent cost-efficacy studies on CC interventions were compared. Methods: We conducted a systematic review of cost-effectiveness studies including only countries with high CC incidence (>14.5) and GDP per capita below the high income group ( |
